StockTipsArenaBeta

BUY Jubilant Pharmova Limited — Rakesh Bansal

BUYJubilant Pharmova Limited
Jubilant Pharmova share price target & all analyst calls

byRakesh BansalHorizon: Swing (≤2wk)29 Sept 2026via CNBC Awaaz.

Entry₹1,059.7Inferred
Target₹1,150
Total upside +8.52%
Stop loss₹1,030-2.80% risk
CMP₹1,057.6Just now
Active-0.20%+8.74%upside left 13d left
Follow Rakesh Bansal for new calls(32% target hit, 121 closed calls)Get alertsWatch JUBLPHARMA for new buy/sell callsGet alertsSee 1 other Swing call on JUBLPHARMASee 148 other Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 30 Sept, 9:17 am IST
3 supporting1 opposing
Supports the BUY call (3)

Jubilant Pharmova secures USFDA approval for Spokane Line 3 manufacturing

NewsGoogle News·27 Sept · 2d ago

(opens in new tab)

1 other SEBI-registered advisor has an active swing BUY call on this stock, issued in the last 14 days

Advisor consensus · same horizon·21 Sept · 1w ago

Jubilant Pharmova FY26 revenue rises 14%; PAT grows 7%

NewsGoogle News·18 Sept · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

MACD below its signal line — bearish momentum

Technicals · macd·30 Sept · today

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

StockTipsArena© 2026 · NSE equities only · Not investment advicePublic beta · data is auto-aggregated from public sources and may contain errors — verify before acting.